The US government has agreed to purchase another 105 million doses of Pfizer’s COVID-19 shots for $3.2 billion. They’re intended for a fall vaccination campaign, even though millions of COVID-19 doses have already been wasted, as demand plummets amidst news of their ineffectiveness.
STORY AT-A-GLANCE
- The U.S. Department of Health and Human Services announced that it, in partnership with the Department of Defense, agreed to purchase another 105 million doses of Pfizer’s COVID-19 shot — for $3.2 billion
- The contract is intended to supply shots for a coming fall injection campaign and includes options to purchase up to 300 million doses
- The decision came after a June 28 meeting of the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), which recommended that an Omicron-specific component be included in COVID-19 booster shots in the U.S.
- Pfizer stands to profit significantly from the contract and has forecast that its COVID-19 shot sales will reach $32 billion in 2022
- VRBPAC voted 19-2 in favor of recommending booster shots that are Omicron-specific, even though panel members expressed uncertainty and guesswork surrounding the booster rollout
Joseph Mercola
Author
Dr. Joseph Mercola is the founder of Mercola.com. An osteopathic physician, best-selling author, and recipient of multiple awards in the field of natural health, his primary vision is to change the modern health paradigm by providing people with a valuable resource to help them take control of their health.
